Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28097739 | 1.00 | LMNA (0.34) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL11319586 | 0.80 | LMNA (0.39) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL28097661 | 0.80 | LMNA (0.39) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL11314672 | 0.80 | LMNA (0.39) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL11326218 | 0.80 | LMNA (0.39) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL8804538 | 0.79 | PDE4A (0.41) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL4669389 | 0.78 | LMNA (0.34) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL9235255 | 0.78 | LMNA (0.44) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL11320333 | 0.78 | LMNA (0.37) | LMNAL3MBTL1KDM4EPDE4ATDP1 | |
| SCHEMBL28315112 | 0.78 | LMNA (0.37) | LMNAL3MBTL1KDM4EPDE4ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0698112-B1 | ONE POT SYNTHESIS OF OLIGOSACCHARIDES USING MULTIPLE ENZYMES AND CMP-SIALIC ACID REGENERATING SYSTEM | SCRIPPS RESEARCH INST (US) | 2002-03-27 | — | — | EP | claimed |
| US-5374541-A | Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-12-20 | — | — | US | claimed |
| WO-2015194199-A1 | METHOD FOR PRODUCING ALKYL-N-ACETYLGLUCOSAMINIDE | 長谷川香料株式会社 | 2015-12-23 | — | — | WO | disclosed |
| US-20060166927-A1 | Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166927-A1 | Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same | IFNG, IFNAR1, IRF3 | LMNA 3391/4885L3MBTL1 4765/4885KDM4E 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.